PRESS RELEASES

Spruce Biosciences Achieves Proof of Concept in Phase 2 Study of Tildacerfont in Congenital Adrenal Hyperplasia

25 March 2019
– Tildacerfont demonstrates meaningful reduction in key disease biomarkers adrenocorticotropic hormone (ACTH), 17-hydroxyprogesterone (17-OHP) and androstenedione (A4)
– Well-tolerated and safe, tildacerfont holds potential as a treatment for patients with congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

 

Spruce Biosciences Announces Presentation of Positive Topline Data from Phase 2 Study of Tildacerfont (SPR001) in Congenital Adrenal Hyperplasia at the 2019 Annual Meeting of the Endocrine Society (ENDO)

08 March 2019
Tildacerfont demonstrates potential to become the first approved therapy for congenital adrenal hyperplasia, a rare endocrine disorder

Read More +

ALL PRESS RELEASES


 

IN THE NEWS

Spruce clears phase II hurdle with lead asset for rare endocrine disorder

26 March 2019
Spruce Biosciences’ tildacerfont (SPR-001) for congenital adrenal hyperplasia (CAH), a rare endocrine disorder, passed muster in a phase II experiment. Proof-of-concept data were disclosed at the Endocrine Society’s annual meeting in New Orleans, ENDO 2019, for the oral corticotrophin-releasing factor type 1 receptor antagonist.

Read More +

 

Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close

13 March 2019
Spruce’s competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.

Read More +

ALL NEWS

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.